VAERS accepts reports of adverse events and reactions that occur following vaccination. Healthcare providers, vaccine manufacturers, and the public can submit reports to the system. While very important in monitoring vaccine safety, VAERS reports alone cannot be used to determine if a vaccine caused or contributed to an adverse event or illness. The reports may contain information that is incomplete, inaccurate, coincidental, or unverifiable. In large part, reports to VAERS are voluntary, which means they are subject to biases. This creates specific limitations on how the data can be used scientifically. Data from VAERS reports should always be interpreted with these limitations in mind.
The strengths of VAERS are that it is national in scope and can quickly provide an early warning of a safety problem with a vaccine. As part of CDC and FDA’s multi-system approach to post-licensure vaccine safety monitoring, VAERS is designed to rapidly detect unusual or unexpected patterns of adverse events, also known as “safety signals.” If a safety signal is found in VAERS, further studies can be done in safety systems such as the CDC’s Vaccine Safety Datalink (VSD) or the Clinical Immunization Safety Assessment (CISA) project. These systems do not have the same scientific limitations as VAERS, and can better assess health risks and possible connections between adverse events and a vaccine.
Key considerations and limitations of VAERS data:
VAERS data available to the public include only the initial report data to VAERS. Updated data which contains data from medical records and corrections reported during follow up are used by the government for analysis. However, for numerous reasons including data consistency, these amended data are not available to the public.
INABILITY TO WORK; FATIGUE; SEIZURES; VOMITING; MUSCLE PAIN; LUNG PAIN; TIREDNESS; CHILLS; This spontaneous report received from a consumer by a Regulatory Authority (RA, PL-URPL-DML-MLP.4401.2.11357.2021) on 22-JUN-2022 and concerned a 36 year old female of unspecified race and ethnic origin. The patient's weight was 55 kilograms, and height was 160 centimeters. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, batch number and expiry date were not reported, expiry: unknown) dose, start therapy date were not reported,1 total, for covid-19 immunisation. Drug start period was reported as 8 hours. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported. On 05-MAY-2021, the patient experienced inability to work (could not work), fatigue (strong fatigue), seizures (cold seizures are hot weather every 5 seconds), vomiting (vomiting an inch of the night), muscle pain (muscle pain in the entire body), lung pain (soreness of my lungs / the next day), tiredness (constantly tired), and chills (strong chills). The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered with sequelae from inability to work, fatigue, seizures, vomiting, muscle pain, lung pain, tiredness, and chills. This report was serious (Other Medically Important Condition).
|COVID19 (COVID19 (JANSSEN))||1||COVID19||JANSSEN||Unknown||Unknown|